A randomized controlled trial to compare the effects of liquid versus powdered recombinant human growth hormone in treating patients with severe burns

Chen,Guoxian; Shao,Huawei; Pan,Xuanliang

doi:10.3892/br.2016.635

A randomized controlled trial to compare the effects of liquid versus powdered recombinant human growth hormone in treating patients with severe burns

Authors:
- Guoxian Chen
- Huawei Shao
- Xuanliang Pan
View Affiliations

Affiliations: Department of Burns, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Published online on: March 22, 2016 https://doi.org/10.3892/br.2016.635
Pages: 551-556
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recombinant human growth hormone (rhGH) promotes protein utilization and synthesis, and is widely used as a therapy to treat severe burns. The present randomized controlled trial evaluated the effects of different forms of rhGH on patients with severe burns. A total of 29 adult severe burns patients were enrolled between February 2009 and November 2011, and randomly assigned to either treatment group (T, liquid rhGH) or control group (C, powder rhGH). From days 5 to 7 following the infliction of burns, both patient groups received rhGH at 0.067 mg/kg/d, once for 10 days. Median serum pre‑albumin levels increased in both groups following treatment, the elevation from baseline was significantly higher in the T group on day 10 compared to the C group (88 mg/l vs. 65 mg/l, P=0.046). C‑reactive protein, fasting plasma glucose and body weight decreased in both groups. Body weight was significantly lower in the T compared to the C group at baseline, Day 5 and Day 10 (P=0.046, P=0.018 and P=0.006, respectively), however the decrease from baseline levels were not significantly different. Wound healing time was similar between groups (P=0.270). In conclusion the early use of liquid rather than powder rhGH may be more beneficial for treating adult patients with severe burns.

View Figures

View References

1	Palmieri TL, Przkora R, Meyer WJ III and Carrougher GJ: Measuring burn injury outcomes. Surg Clin North Am. 94:909–916. 2014. View Article : Google Scholar : PubMed/NCBI
2	Spanholtz TA, Theodorou P, Amini P and Spilker G: Severe burn injuries: Acute and long-term treatment. Dtsch Arztebl Int. 106:607–613. 2009.PubMed/NCBI
3	Al-Mousawi AM, Mecott-Rivera GA, Jeschke MG and Herndon DN: Burn teams and burn centers: The importance of a comprehensive team approach to burn care. Clin Plast Surg. 36:547–554. 2009. View Article : Google Scholar : PubMed/NCBI
4	Williams FN, Herndon DN and Jeschke MG: The hypermetabolic response to burn injury and interventions to modify this response. Clin Plast Surg. 36:583–596. 2009. View Article : Google Scholar : PubMed/NCBI
5	Atiyeh BS, Gunn SW and Dibo SA: Nutritional and pharmacological modulation of the metabolic response of severely burned patients: Review of the literature (Part II)*. Ann Burns Fire Disasters. 21:119–123. 2008.PubMed/NCBI
6	Rojas Y, Finnerty CC, Radhakrishnan RS and Herndon DN: Burns: An update on current pharmacotherapy. Expert Opin Pharmacother. 13:2485–2494. 2012. View Article : Google Scholar : PubMed/NCBI
7	Blizzard RM: History of growth hormone therapy. Indian J Pediatr. 79:87–91. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hwang IT: Efficacy and safety of growth hormone treatment for children born small for gestational age. Korean J Pediatr. 57:379–383. 2014. View Article : Google Scholar : PubMed/NCBI
9	Fukuda I, Hizuka N, Muraoka T and Ichihara A: Adult growth hormone deficiency: Current concepts. Neurol Med Chir (Tokyo). 54:599–605. 2014. View Article : Google Scholar
10	Arce VM, Devesa P and Devesa J: Role of growth hormone (GH) in the treatment on neural diseases: From neuroprotection to neural repair. Neurosci Res. 76:179–186. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kemp SF and Frindik JP: Emerging options in growth hormone therapy: An update. Drug Des Devel Ther. 5:411–419. 2011. View Article : Google Scholar : PubMed/NCBI
12	Chen GX and Han CM: Influence of recombinant human growth hormone on the prognosis of patients with severe burns a prospective multi-center clinical trial. Zhonghua Shao Shang Za Zhi. 21(347): 92005.(In Chinese). PubMed/NCBI
13	Breederveld RS and Tuinebreijer WE: Recombinant human growth hormone for treating burns and donor sites. Cochrane Database Syst Rev. 15:CD0089902012.
14	Liedert B, Forssmann U, Wolna P, Golob M and Kovar A: Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation. BMC Clin Pharmacol. 10:142010. View Article : Google Scholar : PubMed/NCBI
15	Fuhr U, Tuculanu D, Berghout A, Balser S, Schwebig A and Saenger P: Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. Eur J Endocrinol. 162:1051–1058. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wiesbauer J, Prassl R and Nidetzky B: Renewal of the air-water interface as a critical system parameter of protein stability: Aggregation of the human growth hormone and its prevention by surface-active compounds. Langmuir. 29:15240–15250. 2013. View Article : Google Scholar : PubMed/NCBI
17	Iyoda K, Moriwake T, Seino Y and Niimi H: The clinical usefulness of liquid human growth hormone (hGH) (Norditropin SimpleXx in the treatment of GH deficiency. Horm Res. 51(Suppl 3): S113–S115. 1999. View Article : Google Scholar
18	Rousseau AF, Losser MR, Ichai C and Berger MM: ESPEN endorsed recommendations: Nutritional therapy in major burns. Clin Nutr. 32:497–502. 2013. View Article : Google Scholar : PubMed/NCBI
19	Jie W and Wang S: A nutritional formula suitable for adults' burns in China. Chinese Journal of Surgery. 5:262–266. 1992.
20	Gauglitz GG, Williams FN, Herndon DN and Jeschke MG: Burns: Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogues? Curr Opin Clin Nutr Metab Care. 14:176–181. 2011. View Article : Google Scholar : PubMed/NCBI
21	Herndon DN, Barrow RE, Kunkel KR, Broemeling L and Rutan RL: Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg. 212:424–429; discussion 430–421. 1990. View Article : Google Scholar : PubMed/NCBI
22	Cynober L: Laboratory measurements in clinical nutrition. In: Basics in clinical nutrition (4th edition). Sobotka L (eds) and Wei C (translator). Shanghai Jiaotong University Press. (Shanghai). 398–402. 2013.(In Chinese).
23	Branski LK, Herndon DN, Barrow RE, Kulp GA, Klein GL, Suman OE, Przkora R, Meyer W III, Huang T, Lee JO, et al: Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children. Ann Surg. 250:514–523. 2009.PubMed/NCBI
24	Przkora R, Herndon DN, Suman OE, Jeschke MG, Meyer WJ, Chinkes DL, Mlcak RP, Huang T and Barrow RE: Beneficial effects of extended growth hormone treatment after hospital discharge in pediatric burn patients. Ann Surg. 243:796–801; discussion 801–793. 2006. View Article : Google Scholar : PubMed/NCBI